Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with deep vein thrombosis.
Plasma levels of granulocyte-derived elastase (GE-XDP), D-dimer and soluble fibrin (SF) were examined in 53 patients with deep vein thrombosis (DVT) and in 100 healthy volunteers. The mean plasma level of D-dimer was 0.92+/-0.81 microg/ml (+/-S.D.) in healthy volunteers and the mean+2 S.D. value (cutoff value for DVT) was 2.53 microg/ml, which was higher than that used in Europe and North America. Plasma levels of GE-XDP, D-dimer and SF were significantly higher in patients with DVT than in healthy volunteers, and diminished after 1 week of treatment with heparin, urokinase or tissue type plasminogen activator, though were still higher than those of the control subjects. The sensitivity of GE-XDP, D-dimer and SF for DVT was 81.1%, 75.5% and 79.2%, respectively. GE-XDP levels correlated with those of D-dimer and SF. Our results indicate that GE-XDP is a potentially useful marker for the diagnosis of DVT, suggesting that granulocytes are activated in patients with DVT. In our system, the cutoff value of D-dimer for the diagnosis of DVT is higher than in western countries, probably due to the use of different analytical assays.
Kamikura
Yuko
Y
Department of Laboratory Medicine, Mie University School of Medicine, 2-174 Edobashi, Tsu-city, Mie-ken 514-8507, Japan.
Wada
Hideo
H
Nobori
Tsutomu
T
Matsumoto
Takeshi
T
Shiku
Hiroshi
H
Ishikura
Ken
K
Yamada
Norikazu
N
Nakano
Takeshi
T
Kazahaya
Yumiko
Y
Sawai
Tokio
T
Matsuda
Michio
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D005337:Fibrin / Q000032:analysis; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis* / Q000378:metabolism; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D019272:Leukocyte Elastase / Q000097:blood* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology; D020246:Venous Thrombosis / Q000097:blood* / Q000175:diagnosis
D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D005337:Fibrin; D006493:Heparin; D019272:Leukocyte Elastase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator